FTSE MIB
34.488,03 +124,28 (+0,36%) Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
38.460,08 +907,92 (+2,42%) Petrolio
83,39 +0,03 (+0,04%) Bitcoin EUR
62.365,49 +527,95 (+0,85%)
Gilead Sciences, Inc. (GILD.SN)
| Chiusura precedente | 65,55 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 57,39 - 57,39 |
| Intervallo di 52 settimane | 57,39 - 65,55 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | 71,564B |
| Beta (5 anni mensile) | 0,20 |
| Rapporto PE (ttm) | 17,55 |
| EPS (ttm) | 3,27 |
| Prossima data utili | 25 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 14 mar 2024 |
| Stima target 1A | N/D |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
